A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients

被引:79
|
作者
Pillans, PI
Rigby, RJ
Kubler, P
Willis, C
Salm, P
Tett, SE
Taylor, PJ
机构
[1] Princess Alexandra Hosp, Dept Clin Pharmacol, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Princess Alexandra Hosp, Dept Med, Brisbane, Qld 4102, Australia
[3] Princess Alexandra Hosp, Renal Transplantat Unit, Woolloongabba, Qld 4102, Australia
[4] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
关键词
mycophenolic acid; cyclosporin; acute rejection; renal transplantation;
D O I
10.1016/S0009-9120(00)00196-X
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Although monitoring of cyclosporin (CsA) is standard clinical practice postrenal transplantation. mycophenolic acid (MPA) concentrations are not routinely measured. There is evidence that a relationship exists between MPA area under the concentration-time curve (AUC) and rejection. In this study, a retrospective analysis was undertaken of 27 adult renal transplant recipients. Methods: Patients received CsA and MPA therapy and had a four-point MPA AUC investigation. The relationship between MPA AUC performed in the first week after transplantation, as well as median trough cyclosporin concentrations, and clinical outcomes in the first month posttransplant were evaluated. Results: A total of 12 patients experienced biopsy proven rejection (44.4%) and 4 patients had gastrointestinal adverse events (14.8%). A statistically significant relationship was observed between the incidence of biopsy proven rejection and both MPA AUC (p = 0.02) and median trough CsA concentration (p = 0.008). No relationship between trough MPA concentration and rejection was observed (p = 0.21). Only 3 of 11 (27%) patients with an MPA AUC > 30 mg.h/L and a median trough CsA > 175 mug/L experienced acute rejection, compared with a 56% incidence of rejection for the remaining 16 patients. Patients who experienced adverse gastrointestinal events had significantly lower MPA AUC (p = 0.04), but median trough CsA concentrations were not significantly different (p = 0.24). Further, 3 of these 4 patients had rejection episodes. Conclusions: in addition to standard CsA monitoring, we propose further investigation of the use of a 4-point sampling strategy to predict MPA AUC in the first week posttransplant, which may facilitate optimization of mycophenolate mofetil dose at a rime when patients are most vulnerable to acute rejection. (C) 2001 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [31] Maximum A posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods
    Prémaud, A
    Le Meur, Y
    Debord, J
    Szelag, JC
    Rousseau, A
    Hoizey, G
    Toiipance, O
    Marquet, P
    THERAPEUTIC DRUG MONITORING, 2005, 27 (03) : 354 - 361
  • [32] Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients
    Jung, Hee-Yeon
    Lee, Sukyung
    Jeon, Yena
    Choi, Ji-Young
    Cho, Jang-Hee
    Park, Sun-Hee
    Kim, Yong-Lim
    Kim, Hyung-Kee
    Huh, Seung
    Won, Dong Il
    Kim, Chan-Duck
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (24)
  • [33] Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients
    Satoh, Shigeru
    Tada, Hitoshi
    Murakami, Miho
    Tsuchiya, Norihiko
    Li, Zhenhua
    Numakura, Kazuyuki
    Saito, Mitsuru
    Inoue, Tadamitsu
    Miura, Masatomo
    Hayase, Yukitoshi
    Suzuki, Toshio
    Habuchi, Tornonori
    TRANSPLANTATION, 2006, 82 (04) : 486 - 493
  • [34] Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients
    Mino, Yasuaki
    Naito, Takafumi
    Otsuka, Atsushi
    Ozono, Seiichiro
    Kagawa, Yoshiyuki
    Kawakami, Junichi
    CLINICA CHIMICA ACTA, 2009, 409 (1-2) : 56 - 61
  • [35] Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: an analysis of the Mycophenolic acid Observational REnal transplant registry
    Doria, Cataldo
    Greenstein, Stuart
    Narayanan, Mohanram
    Ueda, Kimi
    Wiland, Anne
    McCague, Kevin
    Sankari, Bashir
    Chan, Laurence
    CLINICAL TRANSPLANTATION, 2012, 26 (06) : E602 - E611
  • [36] One Dose of Basiliximab in the Prevention of Acute Rejection in Renal Transplant Recipients
    Tian, Chuan
    Zhang, Xufeng
    Liu, Shuangde
    Yan, Jieke
    Wang, Hongwei
    LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (08): : 1553 - 1557
  • [37] The effects of gusperimus hydrochloride on rejection in renal transplant recipients
    Nagano, T
    Uemura, T
    Kanda, H
    Akiyama, T
    Kurita, T
    JAPANESE JOURNAL OF TRANSPLANTATION, 1996, 31 (04) : 314 - 319
  • [38] Mycophenolic acid in diabetic renal transplant recipients -: Pharmacokinetics and application of a limited sampling strategy
    van Hest, RM
    Mathôt, RAA
    Vulto, AG
    Le Meur, Y
    van Gelder, T
    THERAPEUTIC DRUG MONITORING, 2004, 26 (06) : 620 - 625
  • [39] Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: Effect of cyclosporine and tacrolimus comedication
    Brown, NW
    Aw, MM
    Mieli-Vergani, G
    Dhawan, A
    Tredger, JM
    THERAPEUTIC DRUG MONITORING, 2002, 24 (05) : 598 - 606
  • [40] Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection
    Kranz, Birgitta
    Vester, Udo
    Wingen, Anne-Margret
    Nadalin, Silvio
    Paul, Andreas
    Broelsch, Christoph E.
    Hoyer, Peter F.
    PEDIATRIC TRANSPLANTATION, 2008, 12 (04) : 474 - 478